title: [Clinical Characteristics and Therapeutic Efficacy of Multiple Myeloma Combined with Renal Amyloidosis].
abstract: OBJECTIVE
  To evaluate the clinical characteristics of multiple myeloma (MM) combined with renal amyloidosis and its curative efficacy and prognosis.
  
  
  METHODS
  The clinical data of 22 cases of newly diagnosed multiple myeloma combined with renal amyloidosis treated in our hospital from November 2011 to July 2015 were analyzed retrospectively.
  
  
  RESULTS
  According to Intenational Staging System (ISS), among above-menthioned 22 patients the ISS II accounted for 77.2% (17/22), ISS III accounted for 22.8% (5/22). The patients with renal impairment accounted for 36.4% (8/22), with anemia 40.9% (9/22), with serum album < 35 g/L 86.4% (19/22), with urinary protein positive 100% (22/22). The evaluation of the curative efficacy of the 22 cases was as follows: CR 13.6% (3/22); VGPR 4.5% (1/22); PR 22.8% (5/22); SD 45.5% (10/22); PD 13.6% (3/22). Out of 9 patients with effective treatment, 3 cases (3/9, 33.3%) achieved "improved" in renal amyloidosis, 4 cases (4/9, 44.5%) achieved stable in renal amyloidosis, 2 cases (2/9, 2%) achieved "worsened" in renal amyloidosis. Among 17 cases who were followed up, 7 cases died, 10 cases survived, the average duration of follow-up for these cases was 11 (1-37) months, the median overall survival (OS) time was 19 (95% CI 9.2-28.8) months.
  
  
  CONCLUSIONS
  MM with renal amyloidosis is rare, refractory and has a poor prognosis. Whether there is impairment of kidney function or not, renal amyloidosis shall be taken into consideration if the MM patients got massive proteinuria especially nephritic syndrome. Bortezomib may improve the curative efficacy.
authors.affiliation: Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan Province, China.
authors.forename: Hong-Yong
authors.initials: HY
authors.lastname: Wen
authors.affiliation: Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan Province, China.
authors.forename: Si-Lin
authors.initials: SL
authors.lastname: Gan
authors.affiliation: Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan Province, China.
authors.forename: Jie
authors.initials: J
authors.lastname: Ma
authors.affiliation: Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan Province, China.
authors.forename: Xin-Sheng
authors.initials: XS
authors.lastname: Xie
authors.affiliation: Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan Province, China.
authors.forename: Yan-Fang
authors.initials: YF
authors.lastname: Liu
authors.affiliation: Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan Province, China.
authors.forename: Zhong-Xing
authors.initials: ZX
authors.lastname: Jiang
authors.affiliation: Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan Province, China.
authors.forename: Ling
authors.initials: L
authors.lastname: Sun
authors.affiliation: Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan Province, China.
authors.forename: Lin-Xiang
authors.initials: LX
authors.lastname: Liu
authors.affiliation: Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan Province, China.
authors.forename: Fang
authors.initials: F
authors.lastname: Wang
authors.affiliation: Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan Province, China.
authors.forename: Xiao-Li
authors.initials: XL
authors.lastname: Meng
authors.affiliation: Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan Province, China.
authors.forename: Shao-Qian
authors.initials: SQ
authors.lastname: Chen
authors.affiliation: Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan Province, China.
authors.forename: Yuan-Dong
authors.initials: YD
authors.lastname: Chen
authors.affiliation: Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan Province, China.
authors.forename: Ding-Ming
authors.initials: DM
authors.lastname: Wan
authors.affiliation: Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan Province, China. E-mail: sunhui371@medmail.com.cn.
authors.forename: Hui
authors.initials: H
authors.lastname: Sun
mesh_terms: D000686:Amyloidosis / Q000175:diagnosis* / Q000473:pathology* / Q000628:therapy; D000069286:Bortezomib / Q000627:therapeutic use; D006801:Humans; D007674:Kidney Diseases / Q000175:diagnosis* / Q000473:pathology* / Q000628:therapy; D009101:Multiple Myeloma / Q000175:diagnosis* / Q000473:pathology* / Q000628:therapy; D011379:Prognosis; D011507:Proteinuria / Q000175:diagnosis; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D000069286:Bortezomib